Advances in Treatment of Progressive Multifocal Leukoencephalopathy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34405435.
- Also identified by DOI 10.1002/ana.26198 and PMC identifier 9291129.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865-873.
Medical subject headings
- Adoptive Transfer
- Immune Checkpoint Inhibitors
- Leukoencephalopathy, Progressive Multifocal